查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1474920

美國臨床前 CRO 市場規模、佔有率、趨勢分析報告：按服務、按模型類型、按技術、按最終用途、按州、細分市場預測，2024-2030 年

U.S. Preclinical CRO Market Size, Share & Trends Analysis Report By Service (Bioanalysis & DMPK Studies, Toxicology Testing), By Model Type, By Technology, By End-use, By State, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10個工作天內

價格

美國臨床前CRO市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，美國臨床前CRO市場規模預計將達到59億美元，2024年至2030年複合年成長率為7.1%。

製藥公司增加研發活動支出以及注重降低成本是促進市場成長的因素。

早期和後期藥物開發過程的研發預算顯著增加，預計將有助於市場成長。此外，生物製藥失敗率和相關成本的上升正促使生物製藥和生命科學公司更專注於藥物發現和開發過程的早期階段。這可能會推動臨床前 CRO 市場的成長。

全球阿茲海默症患者數量不斷增加、對尖端基因療法的需求、神經退化性疾病的發病率以及遺傳性疾病的高盛行率是推動先進治療方法成長的一些因素。許多大大小小的生物技術公司都在技術和製造能力方面推動該領域的創新，為市場擴張提供了機會。

此外，最近新產品的核准正在加速研發活動。例如，2023年12月，FDA核准了兩種突破性治療方法－Casgevy和Lyfgenia。作為 12 歲及以上鐮狀細胞疾病患者的第一種基於細胞的基因療法，這些治療方法代表了一個重要的里程碑。

美國臨床前 CRO 市場報告亮點：

  • 藥物發現研究在服務領域佔據主導地位，到 2023 年，其佔有率將達到 29.6%。這是由於生物技術和製藥公司越來越傾向於外包研究以加速藥物發現並降低成本。
  • 由於CRO在生物分析研究中的廣泛應用，生物分析和DMPK研究領域預計將在預測期內呈現最快的複合年成長率。
  • 對個人化醫療和先進療法的需求不斷成長、生命科學公司對核心競爭力的關注以及外包趨勢的上升預計將在預測期內推動市場成長。
  • 2022年8月，藥明康德STA宣佈在美國建立佔地190英畝的新製藥生產園區。該設施將是該公司的第二個設施，提供擴展能力和彈性，以滿足美國和世界各地客戶的需求。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第 3 章美國臨床前 CRO 市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 美國臨床前CRO市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章美國臨床前CRO市場：服務預估與趨勢分析

  • 2023年及2030年服務市場佔有率
  • 細分儀表板
  • 美國臨床前 CRO 市場展望（按服務）
  • 2018-2030年市場規模、預測及趨勢分析

第5章美國臨床前CRO市場：模型類型估算及趨勢分析

  • 2023 年和 2030 年按車型類型市場佔有率
  • 細分儀表板
  • 按模型類型分類的美國臨床前 CRO 市場展望
  • 2018-2030年市場規模、預測及趨勢分析

第6章美國臨床前CRO市場：技術預估與趨勢分析

  • 2023年及2030年技術市場佔有率
  • 細分儀表板
  • 美國臨床前CRO市場，依技術分類的前景
  • 2018-2030年市場規模、預測及趨勢分析

第7章美國臨床前CRO市場：最終用途估算與趨勢分析

  • 2023 年及 2030 年最終用途市場佔有率
  • 細分儀表板
  • 美國臨床前 CRO 市場展望（按最終用途）
  • 2018-2030年市場規模、預測及趨勢分析

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
  • 公司簡介
    • Laboratory Corporation of America
    • Lonza
    • WuXi AppTec, Inc.
    • Eurofins Scientific SE
    • Intertek Group plc
    • Medpace Holdings, Inc.
    • Charles River Laboratories International, Inc.
    • SGA SA
    • Pharmaceutical Product Development, Inc.（Thermo Fisher Scientific, Inc.）
    • ICON plc
    • CROWN bioscience
Product Code: GVR-4-68040-257-3

U.S. Preclinical CRO Market Growth & Trends:

The U.S. preclinical CRO market size is anticipated to reach USD 5.9 billion by 2030, growing at a CAGR of 7.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. Factors such as the increasing expenditure on R&D activities and the focus of pharmaceutical companies on cost reduction are driving the market growth.

There has been a significant increase in the R&D budget for early-stage and late-stage drug development processes, which is expected to contribute to market growth. The rising biopharmaceutical failure rates and the costs they entail have also driven the biopharmaceutical & life sciences companies to focus more on the early stage of the drug discovery and development process. This is likely to propel the growth of the market for preclinical CRO.

The increasing cases of Alzheimer's disease globally, demand for cutting-edge gene therapies, incidence of neurodegenerative diseases, and high prevalence of genetic disorders are some of the factors promoting the growth of advanced therapies. A substantial number of major & small biotechnology companies are driving innovation in this field in terms of technology & manufacturing capabilities, thereby offering commercial opportunities for market expansion.

Furthermore, the recent approval of new products has accelerated R&D activities. For instance, in December 2023, the FDA approved two groundbreaking treatments-Casgevy and Lyfgenia. These treatments mark a significant milestone as the first cell-based gene therapies suggested for the treatment of sickle cell disease in patients aged 12 and older.

U.S. Preclinical CRO Market Report Highlights:

  • Discovery research dominated the service segment with 29.6% share in 2023, owing to the rising trend of outsourcing research in the biotechnology and pharmaceutical companies to accelerate drug discovery and reduce cost.
  • The bioanalysis and DMPK studies segment is expected to witness the fastest CAGR over the forecast period, owing to widescale applications of CROs in bioanalysis studies.
  • Increasing demand for personalized medicine and advanced therapeutics, life science companies focusing on their core competencies, and the increasing trend of outsourcing are expected to drive the market growth over the forecast period.
  • In August 2022, WuXi STA announced its new 190-acre pharmaceutical manufacturing campus in the U.S. This site would be its second facility, offering expanded capacity and flexibility to meet customers' needs in the U.S. and across the globe.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Services
    • 1.2.2. Model Type
    • 1.2.3. Technology
    • 1.2.4. End-use
    • 1.2.5. States
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Services outlook
    • 2.2.2. Model Type outlook
    • 2.2.3. Technology outlook
    • 2.2.4. End-use outlook
    • 2.2.5. States outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Preclinical CRO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising outsourcing trend
      • 3.2.1.2. Increasing focus of life science companies on their core competencies
      • 3.2.1.3. Increasing demand of personalized medicine and advanced therapeutics
      • 3.2.1.4. Increasing pharmaceutical R&D investments
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Monitoring issues and lack of standardization
      • 3.2.2.2. Managing relationships
  • 3.3. U.S. Preclinical CRO Market Analysis Tools
    • 3.3.1. Industry analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Preclinical CRO Market: Services Estimates & Trend Analysis

  • 4.1. Services Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Preclinical CRO Market by Services Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Bioanalysis and DMPK studies
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. In vitro ADME
      • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. In-vivo PK
      • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Toxicology testing
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.2. GLP
      • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.3. Non-GLP
      • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Compound management
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.2. Process R&D
      • 4.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.3. Custom synthesis
      • 4.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.3.4. Others
      • 4.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Chemistry
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.4.2. Medicinal chemistry
      • 4.4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.4.3. Computation chemistry
      • 4.4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Safety pharmacology
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.6. Discovery research
      • 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.6.2. Target identification & screening
      • 4.4.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.6.3. Target validation & functional informatics
      • 4.4.6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.6.4. Lead identification & candidate optimization
      • 4.4.6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.6.5. Preclinical development
      • 4.4.6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.6.6. Other associated workflow
      • 4.4.6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.7. Others
      • 4.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Preclinical CRO Market: Model Type Estimates & Trend Analysis

  • 5.1. Model Type Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. U.S. Preclinical CRO Market by Model Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Small animal models
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2. Mice
      • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3. Rats
      • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.4. Rabbits
      • 5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.5. Others
      • 5.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Large animal models
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2. Pig
      • 5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.3. Others
      • 5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Organoid models
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Cell culture models
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Others
      • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Preclinical CRO Market: Technology Estimates & Trend Analysis

  • 6.1. Technology Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. U.S. Preclinical CRO Market by Technology Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. In vivo studies
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. In vitro studies
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Ex vivo studies
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Imaging technologies
      • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.4.2. Ultrasound imaging
      • 6.4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.4.3. MRI imaging
      • 6.4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.4.4. CT imaging
      • 6.4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.4.5. Radionuclide imaging
      • 6.4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.4.6. Other imaging technologies
      • 6.4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Other technologies
      • 6.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Preclinical CRO Market: End-use Estimates & Trend Analysis

  • 7.1. End-use Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. U.S. Preclinical CRO Market by End-use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Biopharmaceutical companies
      • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 7.4.2. Research and academic institutes
      • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Medical device companies
      • 7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company heat map analysis, 2023
  • 8.4. Company Profiles
    • 8.4.1. Laboratory Corporation of America
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Lonza
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. WuXi AppTec, Inc.
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Eurofins Scientific SE
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Intertek Group plc
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Medpace Holdings, Inc.
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Charles River Laboratories International, Inc.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. SGA SA
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Pharmaceutical Product Development, Inc. (Thermo Fisher Scientific, Inc.)
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. ICON plc
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives
    • 8.4.11. CROWN bioscience
      • 8.4.11.1. Company overview
      • 8.4.11.2. Financial performance
      • 8.4.11.3. Product benchmarking
      • 8.4.11.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. preclinical CRO market, by services, 2018 - 2030 (USD Million)
  • Table 4 U.S. preclinical CRO market, by bioanalysis and DMK studies, 2018 - 2030 (USD Million)
  • Table 5 U.S. preclinical CRO market, by toxicology testing, 2018 - 2030 (USD Million)
  • Table 6 U.S. preclinical CRO market, by compound management, 2018 - 2030 (USD Million)
  • Table 7 U.S. preclinical CRO market, by chemistry, 2018 - 2030 (USD Million)
  • Table 8 U.S. preclinical CRO market, by safety pharmacology, 2018 - 2030 (USD Million)
  • Table 9 U.S. preclinical CRO market, by discovery research, 2018 - 2030 (USD Million)
  • Table 10 U.S. preclinical CRO market, by others, 2018 - 2030 (USD Million)
  • Table 11 U.S. preclinical CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 12 U.S. preclinical CRO market, by small animal models, 2018 - 2030 (USD Million)
  • Table 13 U.S. preclinical CRO market, by large animal models, 2018 - 2030 (USD Million)
  • Table 14 U.S. preclinical CRO market, by organoid models, 2018 - 2030 (USD Million)
  • Table 15 U.S. preclinical CRO market, by cell culture models, 2018 - 2030 (USD Million)
  • Table 16 U.S. preclinical CRO market, by others, 2018 - 2030 (USD Million)
  • Table 17 U.S. preclinical CRO market, by technology, 2018 - 2030 (USD Million)
  • Table 18 U.S. preclinical CRO market, by in vivo studies, 2018 - 2030 (USD Million)
  • Table 19 U.S. preclinical CRO market, by in vitro studies, 2018 - 2030 (USD Million)
  • Table 20 U.S. preclinical CRO market, by ex vivo studies, 2018 - 2030 (USD Million)
  • Table 21 U.S. preclinical CRO market, by imaging technologies, 2018 - 2030 (USD Million)
  • Table 22 U.S. preclinical CRO market, by other technologies, 2018 - 2030 (USD Million)
  • Table 23 U.S. preclinical CRO market, by end-use, 2018 - 2030 (USD Million)
  • Table 24 U.S. preclinical CRO market, by biopharmaceutical companies, 2018 - 2030 (USD Million)
  • Table 25 U.S. preclinical CRO market, by research and academic institutes, 2018 - 2030 (USD Million)
  • Table 26 U.S. preclinical CRO market, by medical device companies, 2018 - 2030 (USD Million)
  • Table 27 U.S. preclinical CRO market, by states, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. preclinical CRO market: market outlook
  • Fig. 9 U.S. preclinical CRO competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 U.S. preclinical CRO market driver impact
  • Fig. 14 U.S. preclinical CRO market restraint impact
  • Fig. 15 U.S. preclinical CRO market: Services movement analysis
  • Fig. 16 U.S. preclinical CRO market: Services outlook and key takeaways
  • Fig. 17 Bioanalysis and DMPK studies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 In vitro ADME market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 In vivo PK market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Toxicology testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 GLP market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Non-GLP market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Compound management market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Process R&D market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Custom synthesis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Chemistry market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Medicinal chemistry market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Computation chemistry market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Safety pharmacology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Discovery research market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Target identification & screening market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Target validation & functional informatics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Lead identification & candidate optimization market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Preclinical development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Other associated workflow market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 U.S. preclinical CRO market: Model type movement analysis
  • Fig. 39 U.S. preclinical CRO market: Model type outlook and key takeaways
  • Fig. 40 Small animal models market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Mice model market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Rats model market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Rabbits model market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Other model market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Large animal models market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Pigs model market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Other model market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Organoid models market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Cell culture models market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 U.S. preclinical CRO market: Technology movement analysis
  • Fig. 52 U.S. preclinical CRO market: Technology outlook and key takeaways
  • Fig. 53 In vivo studies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 In vitro studies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Ex vivo market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Imaging technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Ultrasound imaging market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 MRI imaging market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 CT imaging market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Radionuclide imaging market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Other imaging technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Other technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 U.S. preclinical CRO market: End-use movement analysis
  • Fig. 64 U.S. preclinical CRO market: End-use outlook and key takeaways
  • Fig. 65 Biopharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Research and academic institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Medical device companies market estimates and forecasts, 2018 - 2030 (USD Million)